Case Report

Combination Therapy with Empagliflozin and Insulin Results in Successful Glycemic Control: A Case Report of Uncontrolled Diabetes Caused by Autoimmune Pancreatitis and Subsequent Steroid Treatment

Miyako Kishimoto,1,2 Kazuhide Yamaoki,1,2 and Masayuki Adachi1,2

1Clinical Research Center, Department of Medicine, International University of Health and Welfare, Tochigi, Japan
2Department of Internal Medicine, Sanno Hospital, 8-10-16 Akasaka, Minato, Tokyo 107-0052, Japan

Correspondence should be addressed to Miyako Kishimoto; mkishimoto@iuhw.ac.jp

Received 14 December 2018; Accepted 1 February 2019; Published 14 February 2019

ACADEMIC EDITOR: John Broom

Copyright © 2019 Miyako Kishimoto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A 66-year-old Japanese male presented with thirst, polyuria, and hemoglobin A1c and postprandial glucose levels (13.1% and 529 mg/dL, respectively) that indicated severe hyperglycemia. Based on his high immunoglobulin G4 level and the results of magnetic resonance imaging and magnetic resonance cholangiopancreatography, we diagnosed him with autoimmune pancreatitis. Insulin was initiated to control his diabetes. One month later, the patient commenced on prednisolone therapy for the treatment of autoimmune pancreatitis, after which his total insulin dosage increased to a maximum of 52 units/day. When the prednisolone dosage was later tapered, the patient’s total dosage of insulin was reduced to 42 units/day. However, he had gained 3.6 kg from the start of prednisolone therapy, and 42 units/day was insufficient for maintaining glycemic control. Thus, empagliflozin, a sodium-dependent glucose transporter 2 (SGLT2) inhibitor, was added. Thereafter, we were able to reduce the patient’s total dosage of insulin; it was eventually discontinued with good glycemic control and weight loss. Such results suggest that the combination of insulin with an SGLT2 inhibitor may be a viable option for the treatment of diabetic patients on prednisolone therapy.

1. Introduction

Sodium-dependent glucose transporter 2 (SGLT2) is a protein in the early proximal tubule that reabsorbs the majority of filtered glucose. Inhibitors of SGLT2 enhance urinary glucose excretion, thereby lowering blood glucose levels in an insulin-independent manner. SGLT2 inhibitors have pleiotropic actions, including reduced glomerular hyperfiltration, hypertension, and weight loss [1], which may correlate with reduced cardiovascular risk. In a recent study of patients with type 2 diabetes who were at high risk for cardiovascular events, those who received empagliflozin (an SGLT2 inhibitor) in addition to standard care had lower rates of the primary composite cardiovascular outcome and death from any cause than did those on placebo [2, 3]. As a result of mounting evidence, the American Diabetes Association and the European Association for the Study of Diabetes recently updated their position statements on the management of type 2 diabetes in adults [4, 5]. In their statements, an SGLT2 inhibitor with proven benefit is recommended for the treatment of patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease.

Autoimmune pancreatitis (AIP) is a chronic and progressive inflammatory pancreatic disease that is uniquely characterized by diagnostic images of pancreatic enlargement and irregularly narrowed main pancreatic ducts. It is a condition that responds dramatically to corticosteroid therapy [6–8]. Corticosteroids are frequently used for the treatment of inflammatory conditions and autoimmune diseases, but are widely recognized to cause hyperglycemia and insulin resistance when used at high doses and for long durations [9, 10].
Herein, we report the case of a patient in whom uncontrolled diabetes as a direct result of AIP and subsequent steroid treatment was successfully treated by the addition of empagliflozin to his insulin therapy.

### Case Report

A 66-year-old Japanese man, 177 cm tall and weighing 66 kg (body mass index of 21.1), had been treated for hypertension for more than seven years. He had yearly medical evaluations but was never diagnosed with diabetes (postprandial glucose and hemoglobin A1c [HbA1c] levels in March 2017: 141 mg/dL and 5.4%, respectively). However, results of an annual medical check-up in March 2018 showed remarkable elevation of postprandial glucose and HbA1c levels (265 mg/dL and 11.4%, respectively). The following month (April), he reported symptoms of thirst and polyuria. His postprandial glucose and HbA1c levels on that day were 529 mg/dL and 13.1%, respectively. A high glycoalbumin level (43.2%) also suggested acute glucose elevation (Table 1). The patient’s anti-glutamic acid decarboxylase antibody test was negative; however, because his postprandial C-peptide level was low (1.15 ng/mL), the patient’s pancreas presumably had reduced insulin-secreting capacity. We noted that the patient’s daily life had not changed in years; and he had no diabetic complications such as retinopathy, nephropathy, or neuropathy.

To identify the cause of hyperglycemia, we performed several imaging studies. Abdominal computed tomography, magnetic resonance imaging, and magnetic resonance cholangiopancreatography (MRCP) revealed diffuse swelling that extended from the pancreatic body to tail (Figures 1(a)–1(c)). In addition, MRCP showed narrowing of the associated main pancreatic duct (Figure 1(c)). The patient did not complain of any digestive symptoms such as upper abdominal pain; however, based on the imaging scans and elevation of serum immunoglobulin G4 (IgG4) levels (141.0 mg/dL), we diagnosed him with type 1 AIP.

To control diabetes, the patient began self-administering insulin injections: insulin aspart (Novo Nordisk) three times...
Figure 1: (a) An abdominal computed tomography scan performed on the patient's first visit shows diffuse swelling extending from the pancreatic body to tail. The arrow indicates the affected portion of the pancreas. (b) Magnetic resonance image (T2 weighted image) of the abdomen prior to prednisolone therapy reveals diffuse swelling extending from the pancreatic body to tail. (c) MRCP prior to prednisolone therapy shows narrowing of the main pancreatic duct extending from the pancreatic body to tail.

per day before each meal and insulin degludec (Novo Nordisk) before going to bed. Because tight adjustment of insulin dosage is required for achieving good glycemic control, the patient received a flash glucose monitoring system (Freestyle Libre™; Abbott Diabetes Care, Witney, UK) [11] upon initiation of insulin. He initially had considerable ketosis (Table 1), but, soon after, the levels of total ketone bodies, acetoacetate, and \( \beta \)-hydroxybutyrate declined to the normal range (36 \( \mu \)mol/L, 12 \( \mu \)mol/L, and 24 \( \mu \)mol/L, respectively). By the end of April, the patient’s total insulin dosage was 36 units/day (Figure 2(a)). In May, prednisolone (35 mg/day) was initiated for the treatment of AIP. At that time, 42 units/day of insulin was not sufficient to control glucose elevation (Figure 2(b)); the patient required a maximum of 52 units/day (Figure 2(c)). One month later, IgG4 levels declined to 54.3 mg/dL. The dosage of prednisolone, which was being tapered by 5 mg/day every 2 weeks, was 20–25 mg/day; and the total dosage of insulin was also lower than that of the previous month. However, 42 units/day of insulin was required to maintain glycemic control (Figure 2(d)). In addition, the combination of high-dose insulin and prednisolone caused our patient to gain 3.6 kg weight from the start of prednisolone initiation.

To improve glycemic control, empagliflozin was added to insulin therapy. Because we expected empagliflozin to lower blood glucose levels, we reduced the dosage of insulin to 29 units/day beforehand. Nevertheless, the patient experienced hypoglycemia 1 hour after breakfast and 1 hour after dinner on the day of empagliflozin initiation (Figure 2(e)). By the end of June, 20 days after the addition of empagliflozin, the patient had lost 1.2 kg and his total insulin dosage had declined to 20 units/day (Figure 2(f)). In July, the prednisolone dosage was reduced to 10 mg/day. Because the patient had achieved good glycemic control (postprandial glucose, HbA1c, and glycoalbumin levels: 159 mg/dL, 6.9%, and 14.3%, respectively), the total dosage of insulin was further reduced and then eventually discontinued (Figure 2(g)). Thereafter, he maintained good glycemic control (postprandial glucose and HbA1c levels: 130–180 mg/dL and 5.4–5.8%, respectively) despite receiving only empagliflozin for diabetes (Figure 3). However, his postprandial C-peptide level remained low (1.84 ng/mL), revealing that although the insulin-secreting capacity of his pancreas had slightly recovered, it remained insufficient.

In October, the patient’s prednisolone dosage was 4 mg/day. His follow-up magnetic resonance imaging and MRCP showed that both the diffuse swelling of the pancreatic tail and narrowing of the associated main pancreatic duct had been ameliorated (Figures 4(a) and 4(b)). To date, the patient’s AIP is well controlled and has not relapsed.
Figure 2: The results of continuous glucose monitoring (CGM) with the flash glucose monitoring system. Closed arrowheads indicate the timing of the patient’s meals and insulin injections. Open arrowheads indicate the timing of the patient’s insulin injections before sleep. Values adjacent to the arrowheads indicate the number of units of insulin injected. (a) One representative pattern of CGM prior to initiation of prednisolone. (b) Initiation of 35 mg/day of oral prednisolone. (c) Two days after initiation of prednisolone. Total dosage of insulin was increased to 52 units/day. (d) Because of the amelioration of AIP, prednisolone dosage was reduced to 25 mg/L; however, 42 units/day of insulin was required to maintain glycemic control. (e) First day of empagliflozin administration. Hypoglycemia recorded at 5 AM to 6 AM and approximately 8 PM. (f) Twenty days after empagliflozin initiation. (g) CGM pattern of patient on empagliflozin only.

3. Discussion

The international consensus diagnostic criteria for AIP identify two subtypes: type 1 is characterized by serum IgG4 elevation and the classic histopathological patterns of lymphoplasmacytic sclerosing pancreatitis; type 2 is characterized by idiopathic duct-centric pancreatitis and is not associated with IgG4 levels [12–14]. Although the clinical findings in AIP are nonspecific, the most common presentation is obstructive jaundice and upper abdominal pain [6, 7]. Approximately 40–80% of patients with AIP reportedly also present with diabetes—some with simultaneous onset with AIP and some with exacerbation of preexisting diabetes [8, 14–21]. In addition, some patients develop diabetes after the start of steroid
therapy, the outcome of which varies with regard to glycemic control [17, 18, 20, 22–24].

The diabetes associated with AIP is assumed to be caused by a reduction in insulin secretion. This may be the result of various mechanisms. For one, AIP is characterized by infiltration of cluster of differentiation (CD)8 and CD4 T lymphocytes, which surround ductal cells and secrete cytokines to suppress and destroy β-islet cells of the pancreas [22, 23]. In addition, inflammation and fibrosis of exocrine glands is associated with the obstruction of blood flow in the endocrine glands, that results in ischemia of islet cells and dysfunctional insulin secretion. Furthermore, extensive destruction of the pancreatic islets caused by direct infiltration of inflammatory cells and fibroblasts proliferation also leads to dysfunctional insulin secretion [14, 16, 20, 23–27].

Glucocorticoids are counterhormones against insulin [9, 10], with mechanisms that include reduction of glucose uptake, induction of hepatic glucose production, and direct inhibition of insulin release [28–30]. Glucocorticoid-induced hyperglycemia is a common condition, which is often considered postprandial hyperglycemia [31, 32]. Prominent hyperglycemia is most often observed when individuals with known diabetes take high doses of glucocorticoids, but may also occur with intake of moderate and low doses in individuals without a known risk [29, 31, 33]. The odds ratio for new-onset diabetes mellitus in patients treated with glucocorticoids ranges from approximately 1.5 to 2.5, and the
Although we rechecked for ketosis throughout his treatment. Although our patient initially had prominent ketosis, the reservoir by enhancing renal ketone reabsorption \[54–56\]. It has been reported that pancreatic endocrine function improves after treatment with steroids in 25–45% of patients with AIP \[20, 24, 35\], with some patients eventually achieving a medication-free status \[34\]. Indeed, Miyamoto et al. reported that three months after the start of steroid therapy in patients with AIP and simultaneous onset of diabetes mellitus, 54% of patients experience improvement in diabetes, 36% do not have any change, and 9% have worsening of diabetes \[16\]. In addition, they noted that the long-term positive effect of corticosteroid therapy on glucose tolerance might be greater than its short-term negative effect on insulin \[16\].

Approximately half of patients with AIP-associated pancreatic diabetes are treated with insulin \[35\]. Such therapy is effective in lowering blood glucose. However, patients must be monitored for hypoglycemia and undesirable weight gain, especially when insulin dosage is increased. SGLT2 inhibitors may have glycemic benefits in patients with type 1 or type 2 diabetes who are on insulin therapy \[36\]. Accumulating reports indicate that SGLT2 inhibitors are well tolerated, and their addition to insulin therapy improves glycemic control and reduces body weight such that insulin dosages could sometimes be reduced \[37–52\]. The mechanism was explained by Ferrannini et al., who reported that empagliflozin lowers fasting and postprandial glycemia by inducing glycosuria, which improves \(\beta\) cell function and insulin sensitivity in patients with type 2 diabetes \[53\]. This was noted despite the fall in insulin secretion and tissue glucose disposal, and the rise in endogenous glucose production that occurs after a single dose of 25 mg empagliflozin \[53\]. We were able to reduce our patient’s total insulin dosage upon initiation of empagliflozin. This lowered his risk of hypoglycemia and suppressed weight gain. Although improvement in glycemic control and reduction in total insulin dosage could have been the result of AIP amelioration alone, we believe that empagliflozin accelerated improvement of glycemic control in our patient.

One of the risks of SGLT2 inhibitors is diabetic ketoacidosis (DKA) \[4, 5\]. Similar to classic DKA, ketone accumulation in SGLT2 inhibitor-associated DKA is downstream of insulin deficiency and glucagon elevation, promoting lipolysis and hepatic ketogenesis. SGLT2 inhibitor-enhanced glucosuria effectively lowers plasma glucose levels, which decreases insulin secretion from pancreatic \(\beta\) cells. SGLT2 inhibited-mediated glucosuria and attenuation of sodium reabsorption in the kidneys may also indirectly expand the ketone reservoir by enhancing renal ketone reabsorption \[54–56\]. Although our patient initially had prominent ketosis, the ketosis improved soon after initiation of insulin therapy. Although we rechecked for ketosis throughout his treatment with empagliflozin, no further signs of ketosis were detected.

In conclusion, this case report suggests that the combination of insulin and SGLT2 inhibitor can be effective for the treatment of secondary diabetes, such as prednisolone-induced diabetes associated with the treatment of AIP in our patient. Further studies on a larger scale are required to confirm the effectiveness of this combination for the treatment of diabetes in patients on corticosteroid therapy.

**Ethical Approval**

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and the Helsinki Declaration of 1975, as revised in 2000 and 2008. In addition, this case report was approved by the Ethics Committee of Sanno Hospital.

**Consent**

The authors obtained written informed consent from the patient for publication.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**References**

[1] L. A. Gallo, E. M. Wright, and V. Vallon, “Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences,” *Diabetes and Vascular Disease Research*, vol. 12, no. 2, pp. 78–89, 2015.

[2] B. Zinman, C. Wanner, J. M. Lachin et al., “Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes,” *The New England Journal of Medicine*, vol. 373, no. 22, pp. 2117–2128, 2015.

[3] K. Kaku, J. Lee, M. Matthes, S. Kaspers, J. George, and H.-J. Woerle, "Empagliflozin and cardiovascular outcomes in Asian patients with type 2 diabetes and established cardiovascular disease — results from EMPA-REG OUTCOME®," *Circulation Journal: Official Journal of the Japanese Circulation Society*, vol. 81, no. 2, pp. 227–234, 2017.

[4] M. J. Davies, D. A. D’Alessio, J. Fradkin et al., “Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD),” *Diabetes Care*, vol. 41, no. 12, pp. 2669–2701, 2018.

[5] M. J. Davies, D. A. D’Alessio, J. Fradkin et al., “Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD),” *Diabetologia*, vol. 61, no. 12, pp. 2461–2498, 2018.

[6] A. O. Omiyale, "Autoimmune pancreatitis," *Gland Surgery*, vol. 5, no. 3, pp. 318–326, 2016.

[7] O. Cai and S. Tan, “From pathogenesis, clinical manifestation, and diagnosis to treatment: an overview on autoimmune pancreatitis,” *Gastroenterology Research and Practice*, vol. 2017, Article ID 3246459, 11 pages, 2017.
from pancreatic ductal cells in diabetes associated with active autoimmune chronic pancreatitis, "Diabetes Care, vol. 24, no. 9, pp. 1661–1667, 2001.

[26] T. Ito, K. Kawabe, Y. Arita et al., "Evaluation of pancreatic endocrine and exocrine function in patients with autoimmune pancreatitis," Pancreas, vol. 34, no. 2, pp. 254–259, 2007.

[27] S. Tanaka, T. Kobayashi, K. Nakanishi et al., "Corticosteroid-responsive diabetes mellitus associated with autoimmune pancreatitis: Pathological examinations of the endocrine and exocrine pancreas," Annals of the New York Academy of Sciences, vol. 958, pp. 152–159, 2002.

[28] F. Delaunay, A. Khan, A. Cintra et al., "Pancreatic β cells are important targets for the diabetogenic effects of glucocorticoids," The Journal of Clinical Investigation, vol. 100, no. 8, pp. 2094–2098, 1997.

[29] D. H. Van Raalte, M. Brands, N. J. Van Der Zijl et al., "Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: A randomised controlled trial," Diabetologia, vol. 54, no. 8, pp. 2103–2112, 2011.

[30] D. H. van Raalte, V. Nofrate, M. C. Bunck et al., "Acute and 2-week exposure to prednisolone impair different aspects of β-cell function in healthy men," European Journal of Endocrinology, vol. 162, no. 4, pp. 729–735, 2010.

[31] K. C. J. Yuen, P. A. McDaniel, and M. C. Riddle, "Twenty-four-hour profiles of plasma glucose, insulin, C-peptide and free fatty acid in subjects with varying degrees of glucose tolerance following short-term, medium-dose prednisone (20 mg/day) treatment: Evidence for differing effects on insulin secretion and action," Clinical Endocrinology, vol. 77, no. 2, pp. 224–232, 2012.

[32] J. N. Clore and I. Thurdy-Hay, "Glucocorticoid-induced hyperglycaemia," Endocrine Practice, vol. 15, no. 5, pp. 469–474, 2009.

[33] M. C. Guillford, J. Charlton, and R. Lativo, "Risk of diabetes associated with prescribed glucocorticoids in a large population," Diabetes Care, vol. 29, no. 12, pp. 2728–2729, 2006.

[34] M. Miyazawa, H. Takatori, T. Shimakami et al., "Prognosis of type 1 autoimmune pancreatitis after corticosteroid therapy-induced remission in terms of relapse and diabetes mellitus," PLoS ONE, vol. 12, no. 11, Article ID e0188549, 2017.

[35] T. Ito, T. Nakamura, N. Fujimori et al., "Characteristics of pancreatic diabetes in patients with autoimmune pancreatitis," Journal of Digestive Diseases, vol. 12, no. 3, pp. 210–216, 2011.

[36] Y. Yang, S. Chen, H. Pan et al., "Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes. Systematic review and meta-analysis of randomized controlled trials," Medicine (Baltimore), vol. 96, no. 21, Article ID e6944, 2017.

[37] Y. Seino, D. Yabe, T. Sasaki et al., "Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glagagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, single-arm study," Journal of Diabetes Investigation, vol. 9, no. 2, pp. 332–340, 2018.

[38] H. Ishihara, S. Yamaguchi, I. Nakao, S. Asahina, and T. Sakatani, "Efficacy and safety of iragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): A 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study," Diabetology International, vol. 10, no. 1, pp. 37–50, 2019.

[39] H. Ishihara, S. Yamaguchi, I. Nakao, A. Okitsu, and S. Asahina, "Efficacy and safety of iragliflozin as add-on therapy to insulin...}
in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study,” *Diabetes, Obesity and Metabolism*, vol. 18, no. 12, pp. 1207–1216, 2016.

[40] N. Inagaki, S.-I. Harashima, N. Maruyama, Y. Kawaguchi, M. Goda, and H. Iijima, “Efficacy and safety of canagliflozin in combination with insulin: A double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus,” *Cardiovascular Diabetology*, vol. 15, no. 1, 2016.

[41] N. Inagaki, S.-I. Harashima, K. Kaku et al., “Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus,” *Diabetes, Obesity and Metabolism*, vol. 20, no. 4, pp. 812–820, 2018.

[42] J. P. H. Wilding, V. Woo, K. Rohwedder, J. Sugg, and S. Parikh, “Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years,” *Diabetes, Obesity and Metabolism*, vol. 16, no. 2, pp. 124–136, 2014.

[43] J. Rosenstock, A. Jelaska, G. Frappin et al., “Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes,” *Diabetes Care*, vol. 37, no. 7, pp. 1815–1823, 2014.

[44] J. Rosenstock, A. Jelaska, C. Zeller, G. Kim, U. C. Broedl, and H. J. Woerle, ”Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: A 78-week randomized, double-blind, placebo-controlled trial,” *Diabetes, Obesity and Metabolism*, vol. 17, no. 10, pp. 936–948, 2015.

[45] T. R. Pieber, S. Famulla, J. Eilbracht et al., “Empagliflozin as adjunct to insulin in patients with type 1 diabetes: A 4-week, randomized, placebo-controlled trial (EASE-1),” *Diabetes, Obesity and Metabolism*, vol. 17, no. 10, pp. 928–935, 2015.

[46] E. Araki, Y. Onishi, M. Asano et al., “Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under Insulin therapY) trial,” *Diabetes, Obesity and Metabolism*, vol. 19, no. 4, pp. 562–570, 2017.

[47] G. Das, A. Surya, and H. Abusahmin, “Use of dapagliflozin as an add-on to insulin therapy in patients with suboptimally controlled type 2 diabetes,” *Therapeutic Advances in Endocrinology and Metabolism*, vol. 9, no. 8, pp. 269–270, 2018.

[48] Y. Terauchi, M. Tamura, M. Senda, R. Gunji, and K. Kaku, ”Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS),” *Diabetes, Obesity and Metabolism*, vol. 20, no. 5, pp. 1176–1185, 2018.

[49] B. Neal, V. Perkovic, D. De Zeeuw et al., “Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes,” *Diabetes Care*, vol. 38, no. 3, pp. 403–411, 2015.

[50] E. Araki, Y. Onishi, M. Asano et al., “Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period,” *Journal of Diabetes Investigation*, vol. 7, no. 4, pp. 555–564, 2016.

[51] K. Suzuki, Y. Mitsuma, T. Sato, T. Anraku, and M. Hatta, ”Comparison of combined tofogliflozin and glargine, tofogliflozin added to insulin, and insulin dose-increase therapy in uncontrolled type 2 diabetes,” *Journal of Clinical Medicine Research*, vol. 8, no. 11, pp. 805–814, 2016.

[52] C. Mathieu, P. Dandonia, P. Gillard et al., “Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the depict-2 study): 24-week results from a randomized controlled trial,” *Diabetes Care*, vol. 41, no. 9, pp. 1938–1946, 2018.

[53] E. Ferrannini, E. Muscelli, S. Frascerr et al., “Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients,” *The Journal of Clinical Investigation*, vol. 124, no. 2, pp. 499–508, 2014.

[54] W. Ogawa and K. Sakaguchi, “Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: Possible mechanism and contributing factors,” *Journal of Diabetes Investigation*, vol. 7, no. 2, pp. 135–138, 2016.

[55] R. M. Goldenberg, L. D. Berard, A. Y. Cheng et al., ”SGLT2 inhibitor–associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis,” *Clinical Therapeutics*, vol. 38, no. 12, pp. 2654–2664.e1, 2016.

[56] J. Rosenstock and E. Ferrannini, ”Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors,” *Diabetes Care*, vol. 38, no. 9, pp. 1638–1642, 2015.